Report Detail
Global Drugs for the Treatment of Refractory Gout Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
- RnM4752591 |
- 05 October, 2026 |
- Global |
- 108 Pages |
- GIR |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global Drugs for the Treatment of Refractory Gout market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
Drugs for the treatment of refractory gout encompass a range of therapeutic options aimed at managing severe and persistent symptoms when standard treatments have proven insufficient. Biologic agents,such as interleukin inhibitors,play a crucial role by targeting inflammatory cytokines involved in the pathogenesis of gouty inflammation.Additionally,pegloticase,a recombinant uricase enzyme,is utilized to aggressively lower serum uric acid levels in refractory cases.
This report is a detailed and comprehensive analysis for global Drugs for the Treatment of Refractory Gout market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Drugs for the Treatment of Refractory Gout market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Drugs for the Treatment of Refractory Gout market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Drugs for the Treatment of Refractory Gout market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Drugs for the Treatment of Refractory Gout market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Drugs for the Treatment of Refractory Gout
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Drugs for the Treatment of Refractory Gout market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Biogen, Fresenius Kabi, Novartis, Sobi, Kiniksa Pharmaceuticals, Pfizer, Amgen, Horizon Therapeutics, Qilu Pharmaceutical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Drugs for the Treatment of Refractory Gout market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Interleukin Inhibitors
Tumor Necrosis Factor Inhibitors
PEGylated Recombinant Uricase
Other
Market segment by Application
Hospital and Clinic
Retail Pharmacies
Other
Major players covered
Roche
Biogen
Fresenius Kabi
Novartis
Sobi
Kiniksa Pharmaceuticals
Pfizer
Amgen
Horizon Therapeutics
Qilu Pharmaceutical
Hanwha Chemical
Bio-Thera Solutions
Zhuhai Livzon Biotechnology
Sandoz
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Drugs for the Treatment of Refractory Gout product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Drugs for the Treatment of Refractory Gout, with price, sales quantity, revenue, and global market share of Drugs for the Treatment of Refractory Gout from 2021 to 2026.
Chapter 3, the Drugs for the Treatment of Refractory Gout competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Drugs for the Treatment of Refractory Gout breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Drugs for the Treatment of Refractory Gout market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Drugs for the Treatment of Refractory Gout.
Chapter 14 and 15, to describe Drugs for the Treatment of Refractory Gout sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Drugs for the Treatment of Refractory Gout Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Interleukin Inhibitors
- 1.3.3 Tumor Necrosis Factor Inhibitors
- 1.3.4 PEGylated Recombinant Uricase
- 1.3.5 Other
- 1.4 Market Analysis by Application
- 1.4.1 Overview: Global Drugs for the Treatment of Refractory Gout Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.4.2 Hospital and Clinic
- 1.4.3 Retail Pharmacies
- 1.4.4 Other
- 1.5 Global Drugs for the Treatment of Refractory Gout Market Size & Forecast
- 1.5.1 Global Drugs for the Treatment of Refractory Gout Consumption Value (2021 & 2025 & 2032)
- 1.5.2 Global Drugs for the Treatment of Refractory Gout Sales Quantity (2021-2032)
- 1.5.3 Global Drugs for the Treatment of Refractory Gout Average Price (2021-2032)
2 Manufacturers Profiles
- 2.1 Roche
- 2.1.1 Roche Details
- 2.1.2 Roche Major Business
- 2.1.3 Roche Drugs for the Treatment of Refractory Gout Product and Services
- 2.1.4 Roche Drugs for the Treatment of Refractory Gout Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 Roche Recent Developments/Updates
- 2.2 Biogen
- 2.2.1 Biogen Details
- 2.2.2 Biogen Major Business
- 2.2.3 Biogen Drugs for the Treatment of Refractory Gout Product and Services
- 2.2.4 Biogen Drugs for the Treatment of Refractory Gout Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 Biogen Recent Developments/Updates
- 2.3 Fresenius Kabi
- 2.3.1 Fresenius Kabi Details
- 2.3.2 Fresenius Kabi Major Business
- 2.3.3 Fresenius Kabi Drugs for the Treatment of Refractory Gout Product and Services
- 2.3.4 Fresenius Kabi Drugs for the Treatment of Refractory Gout Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.3.5 Fresenius Kabi Recent Developments/Updates
- 2.4 Novartis
- 2.4.1 Novartis Details
- 2.4.2 Novartis Major Business
- 2.4.3 Novartis Drugs for the Treatment of Refractory Gout Product and Services
- 2.4.4 Novartis Drugs for the Treatment of Refractory Gout Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.4.5 Novartis Recent Developments/Updates
- 2.5 Sobi
- 2.5.1 Sobi Details
- 2.5.2 Sobi Major Business
- 2.5.3 Sobi Drugs for the Treatment of Refractory Gout Product and Services
- 2.5.4 Sobi Drugs for the Treatment of Refractory Gout Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.5.5 Sobi Recent Developments/Updates
- 2.6 Kiniksa Pharmaceuticals
- 2.6.1 Kiniksa Pharmaceuticals Details
- 2.6.2 Kiniksa Pharmaceuticals Major Business
- 2.6.3 Kiniksa Pharmaceuticals Drugs for the Treatment of Refractory Gout Product and Services
- 2.6.4 Kiniksa Pharmaceuticals Drugs for the Treatment of Refractory Gout Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.6.5 Kiniksa Pharmaceuticals Recent Developments/Updates
- 2.7 Pfizer
- 2.7.1 Pfizer Details
- 2.7.2 Pfizer Major Business
- 2.7.3 Pfizer Drugs for the Treatment of Refractory Gout Product and Services
- 2.7.4 Pfizer Drugs for the Treatment of Refractory Gout Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.7.5 Pfizer Recent Developments/Updates
- 2.8 Amgen
- 2.8.1 Amgen Details
- 2.8.2 Amgen Major Business
- 2.8.3 Amgen Drugs for the Treatment of Refractory Gout Product and Services
- 2.8.4 Amgen Drugs for the Treatment of Refractory Gout Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.8.5 Amgen Recent Developments/Updates
- 2.9 Horizon Therapeutics
- 2.9.1 Horizon Therapeutics Details
- 2.9.2 Horizon Therapeutics Major Business
- 2.9.3 Horizon Therapeutics Drugs for the Treatment of Refractory Gout Product and Services
- 2.9.4 Horizon Therapeutics Drugs for the Treatment of Refractory Gout Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.9.5 Horizon Therapeutics Recent Developments/Updates
- 2.10 Qilu Pharmaceutical
- 2.10.1 Qilu Pharmaceutical Details
- 2.10.2 Qilu Pharmaceutical Major Business
- 2.10.3 Qilu Pharmaceutical Drugs for the Treatment of Refractory Gout Product and Services
- 2.10.4 Qilu Pharmaceutical Drugs for the Treatment of Refractory Gout Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.10.5 Qilu Pharmaceutical Recent Developments/Updates
- 2.11 Hanwha Chemical
- 2.11.1 Hanwha Chemical Details
- 2.11.2 Hanwha Chemical Major Business
- 2.11.3 Hanwha Chemical Drugs for the Treatment of Refractory Gout Product and Services
- 2.11.4 Hanwha Chemical Drugs for the Treatment of Refractory Gout Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.11.5 Hanwha Chemical Recent Developments/Updates
- 2.12 Bio-Thera Solutions
- 2.12.1 Bio-Thera Solutions Details
- 2.12.2 Bio-Thera Solutions Major Business
- 2.12.3 Bio-Thera Solutions Drugs for the Treatment of Refractory Gout Product and Services
- 2.12.4 Bio-Thera Solutions Drugs for the Treatment of Refractory Gout Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.12.5 Bio-Thera Solutions Recent Developments/Updates
- 2.13 Zhuhai Livzon Biotechnology
- 2.13.1 Zhuhai Livzon Biotechnology Details
- 2.13.2 Zhuhai Livzon Biotechnology Major Business
- 2.13.3 Zhuhai Livzon Biotechnology Drugs for the Treatment of Refractory Gout Product and Services
- 2.13.4 Zhuhai Livzon Biotechnology Drugs for the Treatment of Refractory Gout Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.13.5 Zhuhai Livzon Biotechnology Recent Developments/Updates
- 2.14 Sandoz
- 2.14.1 Sandoz Details
- 2.14.2 Sandoz Major Business
- 2.14.3 Sandoz Drugs for the Treatment of Refractory Gout Product and Services
- 2.14.4 Sandoz Drugs for the Treatment of Refractory Gout Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.14.5 Sandoz Recent Developments/Updates
3 Competitive Environment: Drugs for the Treatment of Refractory Gout by Manufacturer
- 3.1 Global Drugs for the Treatment of Refractory Gout Sales Quantity by Manufacturer (2021-2026)
- 3.2 Global Drugs for the Treatment of Refractory Gout Revenue by Manufacturer (2021-2026)
- 3.3 Global Drugs for the Treatment of Refractory Gout Average Price by Manufacturer (2021-2026)
- 3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Drugs for the Treatment of Refractory Gout by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Drugs for the Treatment of Refractory Gout Manufacturer Market Share in 2025
- 3.4.3 Top 6 Drugs for the Treatment of Refractory Gout Manufacturer Market Share in 2025
- 3.5 Drugs for the Treatment of Refractory Gout Market: Overall Company Footprint Analysis
- 3.5.1 Drugs for the Treatment of Refractory Gout Market: Region Footprint
- 3.5.2 Drugs for the Treatment of Refractory Gout Market: Company Product Type Footprint
- 3.5.3 Drugs for the Treatment of Refractory Gout Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Drugs for the Treatment of Refractory Gout Market Size by Region
- 4.1.1 Global Drugs for the Treatment of Refractory Gout Sales Quantity by Region (2021-2032)
- 4.1.2 Global Drugs for the Treatment of Refractory Gout Consumption Value by Region (2021-2032)
- 4.1.3 Global Drugs for the Treatment of Refractory Gout Average Price by Region (2021-2032)
- 4.2 North America Drugs for the Treatment of Refractory Gout Consumption Value (2021-2032)
- 4.3 Europe Drugs for the Treatment of Refractory Gout Consumption Value (2021-2032)
- 4.4 Asia-Pacific Drugs for the Treatment of Refractory Gout Consumption Value (2021-2032)
- 4.5 South America Drugs for the Treatment of Refractory Gout Consumption Value (2021-2032)
- 4.6 Middle East & Africa Drugs for the Treatment of Refractory Gout Consumption Value (2021-2032)
5 Market Segment by Type
- 5.1 Global Drugs for the Treatment of Refractory Gout Sales Quantity by Type (2021-2032)
- 5.2 Global Drugs for the Treatment of Refractory Gout Consumption Value by Type (2021-2032)
- 5.3 Global Drugs for the Treatment of Refractory Gout Average Price by Type (2021-2032)
6 Market Segment by Application
- 6.1 Global Drugs for the Treatment of Refractory Gout Sales Quantity by Application (2021-2032)
- 6.2 Global Drugs for the Treatment of Refractory Gout Consumption Value by Application (2021-2032)
- 6.3 Global Drugs for the Treatment of Refractory Gout Average Price by Application (2021-2032)
7 North America
- 7.1 North America Drugs for the Treatment of Refractory Gout Sales Quantity by Type (2021-2032)
- 7.2 North America Drugs for the Treatment of Refractory Gout Sales Quantity by Application (2021-2032)
- 7.3 North America Drugs for the Treatment of Refractory Gout Market Size by Country
- 7.3.1 North America Drugs for the Treatment of Refractory Gout Sales Quantity by Country (2021-2032)
- 7.3.2 North America Drugs for the Treatment of Refractory Gout Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)
8 Europe
- 8.1 Europe Drugs for the Treatment of Refractory Gout Sales Quantity by Type (2021-2032)
- 8.2 Europe Drugs for the Treatment of Refractory Gout Sales Quantity by Application (2021-2032)
- 8.3 Europe Drugs for the Treatment of Refractory Gout Market Size by Country
- 8.3.1 Europe Drugs for the Treatment of Refractory Gout Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Drugs for the Treatment of Refractory Gout Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Drugs for the Treatment of Refractory Gout Sales Quantity by Type (2021-2032)
- 9.2 Asia-Pacific Drugs for the Treatment of Refractory Gout Sales Quantity by Application (2021-2032)
- 9.3 Asia-Pacific Drugs for the Treatment of Refractory Gout Market Size by Region
- 9.3.1 Asia-Pacific Drugs for the Treatment of Refractory Gout Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Drugs for the Treatment of Refractory Gout Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)
10 South America
- 10.1 South America Drugs for the Treatment of Refractory Gout Sales Quantity by Type (2021-2032)
- 10.2 South America Drugs for the Treatment of Refractory Gout Sales Quantity by Application (2021-2032)
- 10.3 South America Drugs for the Treatment of Refractory Gout Market Size by Country
- 10.3.1 South America Drugs for the Treatment of Refractory Gout Sales Quantity by Country (2021-2032)
- 10.3.2 South America Drugs for the Treatment of Refractory Gout Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Drugs for the Treatment of Refractory Gout Sales Quantity by Type (2021-2032)
- 11.2 Middle East & Africa Drugs for the Treatment of Refractory Gout Sales Quantity by Application (2021-2032)
- 11.3 Middle East & Africa Drugs for the Treatment of Refractory Gout Market Size by Country
- 11.3.1 Middle East & Africa Drugs for the Treatment of Refractory Gout Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Drugs for the Treatment of Refractory Gout Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)
12 Market Dynamics
- 12.1 Drugs for the Treatment of Refractory Gout Market Drivers
- 12.2 Drugs for the Treatment of Refractory Gout Market Restraints
- 12.3 Drugs for the Treatment of Refractory Gout Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of Drugs for the Treatment of Refractory Gout and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Drugs for the Treatment of Refractory Gout
- 13.3 Drugs for the Treatment of Refractory Gout Production Process
- 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Drugs for the Treatment of Refractory Gout Typical Distributors
- 14.3 Drugs for the Treatment of Refractory Gout Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Drugs for the Treatment of Refractory Gout. Industry analysis & Market Report on Drugs for the Treatment of Refractory Gout is a syndicated market report, published as Global Drugs for the Treatment of Refractory Gout Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Drugs for the Treatment of Refractory Gout market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
